Home › NDC Lookup › Ingredients › Amlodipine And Atorvastatin › 58151-0066-93
⚪image loading
(from DailyMed)

Caduet amlodipine and atorvastatin 5 mg; 40 mg Tablet, Film Coated, 30-count — NDC 58151-066-93 (Billing 58151-0066-93)

by Viatris Specialty LLC · 30 TABLET, FILM COATED in 1 BOTTLE

This is a package of 30 tablets of Caduet amlodipine and atorvastatin 5 mg; 40 mg Tablet, Film Coated from Viatris Specialty LLC, marketed since Feb 2026 and currently FDA-listed. It is this product's only package size.

NDC 58151-0066-93
🏷️ FDA NDC (as labeled) 58151-066-93 billing pads the product segment with a zero
Rx only Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 58151-066-93 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
58151 labeler · 066 product · 93 package
Package marketed since
Feb 26, 2026
Sample package
No — commercial package
Listing certified through
Dec 31, 2027
Billing quantity
30 EA per package
Barcode (UPC-A, from the NDC)
3 5815106693 3
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 58151-066-93
Product NDC 58151-066
11-digit billing NDC 58151006693
NCPDP billing unit EA — each (per item)
Application # NDA021540
SPL Set ID 296e89a8-84fb-4431-85e5-46c2f7b1ded6
Established class (EPC) Calcium Channel Blocker; Dihydropyridine Calcium Channel Blocker; HMG-CoA Reductase Inhibitor; Hydroxymethylglutaryl-CoA Reductase Inhibitors
Mechanism of action Calcium Channel Antagonists; Cytochrome P450 3A Inhibitors
Chemical class Dihydropyridines
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2026-02-26
Route ORAL
Dosage form TABLET, FILM COATED
Substance AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM TRIHYDRATE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 053691
GCN 21393
HICL code 025951
Ingredient (HICL) Amlodipine/Atorvastatin
HIC1 code M
Therapeutic class — broad (HIC1) Blood
HIC2 code M4
Therapeutic class — intermediate (HIC2) Affect Blood Lipids/Sugar/Amino Acids
HIC3 code M4I
Therapeutic class — specific (HIC3) Antihyperlipid- Hmg-Coa Ri-Calcium Channel Blocker
AHFS code 24:06.08.00
AHFS class Hmg-Coa Reductase Inhibitors
FDB label name CADUET 5 MG-40 MG TABLET
FDB brand name Caduet
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 053691
  • GCN: 21393
  • HICL (First Databank): 025951
  • AHFS class code: 24:06.08.00
Why two NDCs? The FDA registers this code as 58151-066-93 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 58151-0066-93. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name CADUET 5 MG-40 MG TABLET Ingredient Amlodipine/Atorvastatin
📖 What it is MedlinePlus · NLM

Amlodipine is used to treat high blood pressure and certain types of angina (chest pain) and coronary artery disease (narrowing of the blood vessels that supply blood to the heart). Amlodipine is in a class of medications called calcium channel blockers. It lowers blood pressure by relaxing the blood vessels so the heart does not have to pump as hard. It controls chest pain by increasing the supply of blood to the heart. If taken regularly, amlodipine controls chest pain, but it does not stop chest pain once it starts. Your doctor may prescribe a different medication to take when you have ches...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It combines two medicines in one tablet. Amlodipine treats high blood pressure and angina from coronary artery disease. Atorvastatin helps lower cholesterol and prevent cardiovascu...
  • Take it by mouth once a day. Any time of day works, and you can take it with or without food. Following your prescriber's directions and your label is the best approach.
  • Some people notice swelling in the ankles or feet, dizziness, flushing, palpitations, tiredness or nausea. Others have joint pain, diarrhea or cold-like symptoms. Tell me or your d...
  • Call promptly if you have muscle pain, tenderness or weakness you can't explain, especially with fever. Also call for yellow skin or eyes, worsening chest pain or signs of an aller...
📖 Read our full Amlodipine / Atorvastatin guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
58151-0066-93 You're viewing this Main listing 30 TABLET, FILM COATED in 1 BOTTLE 2026-02-26 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Amlodipine and atorvastatin 5 mg/1; 40 mg 00378-4515-93 Mylan 30 tablets $1.191 AB Availability likely —
Amlodipine and Atorvastatin 5 mg/1; 40 mg 60505-3488-03 Apotex 30 tablets $1.191 AB Availability likely —
Amlodipine and Atorvastatin 5 mg/1; 40 mg 62332-0760-30 Alembic 30 tablets $1.191 AB Availability likely —
Amlodipine and Atorvastatin 5 mg/1; 40 mg 66993-0268-30 Prasco 30 tablets $1.191 AB Availability likely —
Caduet 5 mg/1; 40 mg 00069-6565-30 Pfizer 30 tablets — AB FDA listed —
Amlodipine besylate and Atorvastatin calcium 5 mg/1; 40 mg 43598-0316-05 Dr. 500 tablets — AB FDA listed —
Amlodipine and Atorvastatin 5 mg/1; 40 mg 46708-0760-30 Alembic 30 tablets — AB FDA listed —
Caduet 5 mg/1; 40 mgthis 58151-0066-93 Viatris 30 tablets — AB FDA listed —
Amlodipine and Atorvastatin 5 mg/1; 40 mg 72162-2094-03 Bryant 30 tablets — AB FDA listed —
About this product: this is the brand-name version. FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2026
On the market since
Feb 2026
📍
2026
Currently FDA-listed
listed with the FDA
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Amlodipine / Atorvastatin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerViatris Specialty LLC
Application holderPHARMACIA AND UPJOHN CO LLC
FDA applicationNDA021540 (NDA)
Labeler code58151
First marketedFeb 2026
Product typeHuman Prescription Drug
Portfolio122 products on file

More NDCs from Viatris Specialty LLC labeler code 58151

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Caduet — the program that covers self-administered drugs. 2 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Caduet. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$57.4K
Claims incl. refills
40
Beneficiaries
30
Spend / beneficiary
$1,913.67
Spend / claim
$1,435.25
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Caduet (this brand).

Top reported reactions

Dizziness184
Nausea176
Fatigue171
Malaise163
Pain147
Dyspnoea144
Death143

Age at onset

Child1
Adolescent1
Adult75
Elderly190

Reporter sex

0 reports

Serious outcomes

Hospitalization1,071
Death356
Life-threatening92
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 177 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Viatris Specialty LLC. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Viatris Specialty LLC is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 58151-0065-93 · Viatris 58151-0067-93 · Viatris →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.